DK0483961T3 - Specifikke bindemidler - Google Patents

Specifikke bindemidler

Info

Publication number
DK0483961T3
DK0483961T3 DK91308147T DK91308147T DK0483961T3 DK 0483961 T3 DK0483961 T3 DK 0483961T3 DK 91308147 T DK91308147 T DK 91308147T DK 91308147 T DK91308147 T DK 91308147T DK 0483961 T3 DK0483961 T3 DK 0483961T3
Authority
DK
Denmark
Prior art keywords
human antibody
reshaped
specific binders
hmfg1
hmfg
Prior art date
Application number
DK91308147T
Other languages
English (en)
Inventor
Martine Elisa Verhoeyen
Original Assignee
Cancer Rec Tech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cancer Rec Tech Ltd filed Critical Cancer Rec Tech Ltd
Application granted granted Critical
Publication of DK0483961T3 publication Critical patent/DK0483961T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
  • Pretreatment Of Seeds And Plants (AREA)
  • Nonmetallic Welding Materials (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK91308147T 1990-09-07 1991-09-05 Specifikke bindemidler DK0483961T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB909019553A GB9019553D0 (en) 1990-09-07 1990-09-07 Specific binding agents

Publications (1)

Publication Number Publication Date
DK0483961T3 true DK0483961T3 (da) 2003-06-23

Family

ID=10681827

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91308147T DK0483961T3 (da) 1990-09-07 1991-09-05 Specifikke bindemidler

Country Status (18)

Country Link
US (2) US6204366B1 (da)
EP (1) EP0483961B1 (da)
JP (2) JP3514456B2 (da)
KR (1) KR930702526A (da)
AT (1) ATE233279T1 (da)
AU (1) AU653167B2 (da)
BG (1) BG60716B1 (da)
CA (1) CA2090961C (da)
DE (1) DE69133200T2 (da)
DK (1) DK0483961T3 (da)
ES (1) ES2193129T3 (da)
FI (2) FI113873B (da)
GB (1) GB9019553D0 (da)
HU (2) HUT67796A (da)
NO (2) NO314595B1 (da)
RO (1) RO113432B1 (da)
UA (1) UA46691C2 (da)
WO (1) WO1992004380A1 (da)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US6407213B1 (en) 1991-06-14 2002-06-18 Genentech, Inc. Method for making humanized antibodies
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5869619A (en) * 1991-12-13 1999-02-09 Xoma Corporation Modified antibody variable domains
CA2507749C (en) * 1991-12-13 2010-08-24 Xoma Corporation Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
WO1994011508A2 (en) * 1992-11-13 1994-05-26 Cancer Research Fund Of Contra Costa Polypeptides with specificity for neoplasias, kit, and diagnostic, vaccination, and therapeutic methods
JPH09503901A (ja) * 1992-11-16 1997-04-22 キャンサー リサーチ ファンド オブ コントラ コスタ 広範な新生物特異性を有するペプチドおよびアンチセンスペプチド
US6281335B1 (en) * 1993-10-08 2001-08-28 Coulter Corporation Hybridoma and anti-KC-4 humanized monoclonal antibody
US5792852A (en) * 1992-11-16 1998-08-11 Cancer Research Fund Of Contra Costa Polynucleotides encoding modified antibodies with human milk fat globule specificity
US5804187A (en) 1992-11-16 1998-09-08 Cancer Research Fund Of Contra Costa Modified antibodies with human milk fat globule specificity
JPH07203974A (ja) * 1994-01-13 1995-08-08 Tosoh Corp 癌特異的ムチンを認識する抗体の遺伝子断片等
EP0781847A1 (en) * 1995-11-06 1997-07-02 MERCK PATENT GmbH Humanized monoclonal antibody
AU763029B2 (en) * 1997-11-14 2003-07-10 Euro-Celtique S.A. Immunoglobulin molecules having a synthetic variable region and modified specificity
GB2360771A (en) * 2000-03-28 2001-10-03 Antisoma Res Ltd Compounds for targeting
WO2001074905A1 (en) * 2000-04-03 2001-10-11 Antisoma Research Limited Compounds for targeting
AU2002307064A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Immunoglobulin construct containing anti-mucin variable domain sequences for eliciting an anti-idiotype anti-tumor response
GB0200657D0 (en) * 2002-01-12 2002-02-27 Antisoma Plc Cancer treatment
JP4753578B2 (ja) * 2002-06-03 2011-08-24 ジェネンテック, インコーポレイテッド 合成抗体ファージライブラリー
WO2004007687A2 (en) * 2002-07-16 2004-01-22 Stuart Bussell Methods to construct multimeric dna and polymeric protein sequences as direct fusions or with linkers
JP2007501011A (ja) * 2003-08-01 2007-01-25 ジェネンテック・インコーポレーテッド 制限多様性配列を有する結合型ポリペプチド
GB0519398D0 (en) * 2005-09-23 2005-11-02 Antisoma Plc Biological materials and uses thereof
WO2007056441A2 (en) 2005-11-07 2007-05-18 Genentech, Inc. Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1973951A2 (en) * 2005-12-02 2008-10-01 Genentech, Inc. Binding polypeptides with restricted diversity sequences
RU2600444C2 (ru) * 2010-10-13 2016-10-20 Янссен Байотек, Инк. Человеческие антитела к онкостатину м и способы их применения
US20140079722A1 (en) * 2011-03-09 2014-03-20 Centrose, Llc Extracellular targeted drug conjugates
RU2493165C1 (ru) * 2012-02-28 2013-09-20 Общество с ограниченной ответственностью "Технофарма" Наноантитело, специфически связывающее белок muc1, способ детекции белка muc1 с помощью наноантител
JP6416751B2 (ja) 2012-04-30 2018-10-31 バイオセラ インコーポレイテッド β−グルカン免疫治療方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) * 1986-03-27 1986-04-30 Winter G P Recombinant dna product
AU1103988A (en) * 1987-01-07 1988-07-27 Imperial Cancer Research Technology Limited Probe
WO1988009344A1 (en) * 1987-05-21 1988-12-01 Creative Biomolecules, Inc. Targeted multifunctional proteins
AU3049189A (en) * 1988-02-08 1989-08-25 John Muir Cancer & Aging Institute Monoclonal antibody specific to a novel mucin-like glycoprotein surface antigen on human carcinoma cells
EP0442926A1 (en) * 1988-11-10 1991-08-28 Imperial Cancer Research Technology Limited Polypeptides
CA2003211A1 (en) 1988-11-17 1990-05-17 Pei-Xiang Xing Monoclonal antibodies
US5075219A (en) * 1989-04-05 1991-12-24 John Muir Cancer & Aging Institute Monoclonal antibody which recognizes a specific glycoprotein of a human milk-fat globule membrane mucin antigen and said mucin antigen
HUT64600A (en) * 1989-11-17 1994-01-28 Unilever Nv Method for producing specific binding materials

Also Published As

Publication number Publication date
ATE233279T1 (de) 2003-03-15
CA2090961C (en) 2004-01-20
AU653167B2 (en) 1994-09-22
FI114611B (fi) 2004-11-30
RO113432B1 (ro) 1998-07-30
JP3514456B2 (ja) 2004-03-31
FI113873B (fi) 2004-06-30
JPH06500468A (ja) 1994-01-20
WO1992004380A1 (en) 1992-03-19
NO314595B1 (no) 2003-04-14
DE69133200D1 (de) 2003-04-03
NO930825L (no) 1993-05-05
HUT67796A (en) 1995-04-28
NO20014822L (no) 1993-05-05
FI930984A0 (fi) 1993-03-05
NO930825D0 (no) 1993-03-05
BG97607A (bg) 1994-03-31
AU8495391A (en) 1992-03-30
US6204366B1 (en) 2001-03-20
UA46691C2 (uk) 2002-06-17
DE69133200T2 (de) 2003-11-20
EP0483961B1 (en) 2003-02-26
NO315239B1 (no) 2003-08-04
BG60716B1 (en) 1996-01-31
HU9300609D0 (en) 1993-05-28
CA2090961A1 (en) 1992-03-08
NO20014822D0 (no) 2001-10-04
ES2193129T3 (es) 2003-11-01
KR930702526A (ko) 1993-09-09
FI930984A (fi) 1993-03-05
EP0483961A1 (en) 1992-05-06
JP2003061689A (ja) 2003-03-04
GB9019553D0 (en) 1990-10-24
US20020086978A1 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
ES2193129T3 (es) Ligantes especificos.
PT99934A (pt) Processo para a producao de um anticorpo anti-htnf alfa recombinante ou humanizado
FI840219A (fi) Human-humanhybridom foer neoplasmer.
DE3751585T2 (de) Hybridome, die monoklonale Antikörper gegen neue Mucin-Epitope produzieren.
DE3687736D1 (de) Monoklonale antikoerper gegen humanen brustkrebs, korrespondierende hybridome, deren herstellung und verwendung.
FI922220A (fi) Specifika bindemedel.
NO174110C (no) Monoklonalt antistoff til anvendelse in vitro for diagnose av maligne tumor- eller akutte inflammasjonssykdommer, og som er spesifikt for N-acetyl-neuraminsyre i hybridom som produserer antistoffet
DE3580524D1 (de) Monoklonaler antikoerper geeignet zur spezifischen unterscheidung von humanen hepatokarzinomzellen.
DE3881101D1 (de) Monoklonal-antikoerper und methode fuer die bereitung von hybridoma, produzierend diese antikoerper.
RU93058456A (ru) Антитела, способы диагностики, способ лечения, фармацевтическая композиция, клеточные линии
ATE84069T1 (de) Murin-hybridoma lym-2 und diagnostikantikoerper, der dadurch hergestellt ist.
FR2697088B1 (fr) Anticorps monoclonaux pour le diagnostic différentiel de cancers épithéliaux dans des épanchements séreux, hybridomes les secrétant et kit de diagnostic.
DK1414859T5 (da) Monoklonale anti-SSRP-1-antistoffer og hybridomer som producerer antistofferne